

Appl. No. 09/775,048  
Amdt. Dated August 11, 2003  
Reply to Office Action of March 11, 2003

**IN THE CLAIMS:**

Claims 1-3 (Cancelled).

Claim 4. (Currently amended) A method of modulating physiology or development of an IL-1R6 receptor expressing cell comprising contacting ~~said~~ the cell to an exogenous ~~agonist or~~ antagonist of a mammalian IL-1 $\epsilon$  or IL-1 $\delta$  (SEQ ID NOs:4 or 10), wherein the antagonist is:

- a) a composition derived from the antigen-binding site of an antibody that specifically binds to IL-1 $\epsilon$  or IL-1R6 (SEQ ID NOs:13 or 15); or
- b) IL-1 $\delta$  (SEQ ID NOs:2 or 11).

Claim 5. (Currently amended) The method of Claim 4, wherein:

A) ~~said~~ the antagonist is:

1) an antibody which:

~~a) neutralizes said mammalian IL-1 $\delta$ ; or~~

~~b) neutralizes said the mammalian IL-1 $\epsilon$  or IL-1R6; or~~

2) ~~a mutein of said IL-1 $\delta$  or IL-1 $\epsilon$ ;~~

B) ~~said~~ the physiology is selected from:

1) proliferation;

2) tissue remodeling; or

3) production of inflammatory mediators, including cytokines, chemokines, or adhesion molecules; or

C) ~~said modulating is specific for epithelial cells and not endothelial cells~~  
the cell is an epithelial cell.

Claim 6. (Currently amended) The method of ~~Claim 4~~ Claim 5, wherein:

a) ~~said antagonist is an antibody and said the~~ physiology is an inflammatory response; ~~or~~

b) ~~said modulating is specific for Th2 cells and not Th1 cells.~~

Appl. No. 09/775,046  
Amdt. Dated August 11, 2003  
Reply to Office Action of March 11, 2003

Claim 7. (Currently amended) The method of ~~Claim 4~~ Claim 6, wherein ~~said the~~ modulating is ~~blocking, and said physiology is an inflammatory response~~ inhibition.

Claim 8. (Currently amended) A method of modulating a signal to a cell mediated by ~~IL-1 $\delta$  or IL-1 $\epsilon$~~  (SEQ ID NOs:4 or 10) comprising contacting ~~said the~~ cell to an administered ~~agonist or antagonist~~ of IL-1R6 (SEQ ID NOs:13 or 15), wherein the antagonist is:

- a) a composition derived from the antigen-binding site of an antibody that specifically binds to IL-1 $\epsilon$  or IL-1R6; or
- b) IL-1 $\delta$  (SEQ ID NOs:2 or 11).

Claim 9. (Currently amended) The method of Claim 8, wherein ~~said the~~ modulating is inhibiting, and ~~said the~~ signal is a pro-inflammatory signal.

a<sup>3</sup>  
Claim 10. (Currently amended) The method of ~~Claim 9~~ Claim 8, wherein:

- a) ~~said the~~ antagonist is a neutralizing antibody to IL-1 $\epsilon$  or IL-1R6;
- b) ~~said agonist or antagonist is administered in combination with an~~ antagonist or agonist of CXCR1, CXCR2, or CCR6; or
- c) ~~said agonist or antagonist is administered in combination with a growth~~ factor, cytokine, chemokine, or immune adjuvant.

Claims 11-20. (Cancelled).

---